Glukagonlignende peptid 1-receptoragonisten semaglutid

Amalie Dyhrberg Boje; Christian Rimer Juhl; Signe Sørensen Torekov; Sten Madsbad

Glukagonlignende peptid 1-receptoragonisten semaglutid

Amalie Dyhrberg Boje, Christian Rimer Juhl, Signe Sørensen Torekov, Sten Madsbad

Endokrinologisk Forskningsenhed AHH

Abstract

Semaglutide is a glucagon-like peptide-1 receptor-agonist (GLP-1 RA), which is injected subcutaneously once a week for treatment of Type 2 diabetes. In this review, the present results of semaglutide treatment are presented. Semaglutide has been evaluated in more than 8,000 patients across the spectrum of Type 2 diabetes. Trials with semaglutide have demonstrated superiority with sustained improved glycaemic control and weight loss compared to oral antidiabetic agents, other GLP-1 RAs and basalinsulin. In addition, semaglutide significantly decreased the occurrence of cardiovascular events compared with standard pharmacological diabetic treatment combined with placebo.

Bidragets oversatte titel	The glucagon-like peptide-1 receptor-agonist semaglutide
Originalsprog	Dansk
Tidsskrift	Ugeskrift for Laeger
Vol/bind	181
ISSN	0041-5782
Status	Udgivet - 7 okt. 2019

Citationsformater

@article{941f3b1f63404146b2c66353aab3afba,

title = "Glukagonlignende peptid 1-receptoragonisten semaglutid",

abstract = "Semaglutide is a glucagon-like peptide-1 receptor-agonist (GLP-1 RA), which is injected subcutaneously once a week for treatment of Type 2 diabetes. In this review, the present results of semaglutide treatment are presented. Semaglutide has been evaluated in more than 8,000 patients across the spectrum of Type 2 diabetes. Trials with semaglutide have demonstrated superiority with sustained improved glycaemic control and weight loss compared to oral antidiabetic agents, other GLP-1 RAs and basalinsulin. In addition, semaglutide significantly decreased the occurrence of cardiovascular events compared with standard pharmacological diabetic treatment combined with placebo.",

author = "Boje, \{Amalie Dyhrberg\} and Juhl, \{Christian Rimer\} and Torekov, \{Signe S{\o}rensen\} and Sten Madsbad",

year = "2019",

month = oct,

day = "7",

language = "Dansk",

volume = "181",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

}

TY - JOUR

T1 - Glukagonlignende peptid 1-receptoragonisten semaglutid

AU - Boje, Amalie Dyhrberg

AU - Juhl, Christian Rimer

AU - Torekov, Signe Sørensen

AU - Madsbad, Sten

PY - 2019/10/7

Y1 - 2019/10/7

N2 - Semaglutide is a glucagon-like peptide-1 receptor-agonist (GLP-1 RA), which is injected subcutaneously once a week for treatment of Type 2 diabetes. In this review, the present results of semaglutide treatment are presented. Semaglutide has been evaluated in more than 8,000 patients across the spectrum of Type 2 diabetes. Trials with semaglutide have demonstrated superiority with sustained improved glycaemic control and weight loss compared to oral antidiabetic agents, other GLP-1 RAs and basalinsulin. In addition, semaglutide significantly decreased the occurrence of cardiovascular events compared with standard pharmacological diabetic treatment combined with placebo.

AB - Semaglutide is a glucagon-like peptide-1 receptor-agonist (GLP-1 RA), which is injected subcutaneously once a week for treatment of Type 2 diabetes. In this review, the present results of semaglutide treatment are presented. Semaglutide has been evaluated in more than 8,000 patients across the spectrum of Type 2 diabetes. Trials with semaglutide have demonstrated superiority with sustained improved glycaemic control and weight loss compared to oral antidiabetic agents, other GLP-1 RAs and basalinsulin. In addition, semaglutide significantly decreased the occurrence of cardiovascular events compared with standard pharmacological diabetic treatment combined with placebo.

M3 - Tidsskriftartikel

C2 - 31610830

SN - 0041-5782

VL - 181

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

ER -

Glukagonlignende peptid 1-receptoragonisten semaglutid

Abstract

Fingeraftryk

Citationsformater